Advertisement
Screener

AbCellera Biologics Inc. (ABCL) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

AbCellera Biologics Inc. Cash Flow Breakdown

Cash flow breakdown shows where AbCellera Biologics Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $131.29M went out.
  • Fiscal year ended 2025-12-31: from investing, $87.75M came in.
  • Fiscal year ended 2025-12-31: from financing, $14.08M came in.
  • Fiscal year ended 2025-12-31: change in cash, $28.37M went out.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDebt paid backNew debtCommercial paperNew shares soldNot split outChange in cash
2025-12-31-$131.29M$87.75M$14.08M*-$28.37M
2024-12-31-$108.56M$121.41M$12.77M*$23.00M
2023-12-31-$43.88M-$221.11M$10.36M*-$254.04M
2022-12-31$277.36M-$352.63M-$1.63M*-$86.49M
2021-12-31$244.58M-$332.25M-$3.89M*-$92.97M
2020-12-31$22.69M-$119.78M$522.84M$160.81M*$586.56M
2019-12-31$2.69M-$5.78M-$399.00K$193.00K$387.00K$25.00K-$2.89M

Each quarter (3 month)

Quarter endRunning the businessFrom investingDebt paid backNew debtNew shares soldNot split outChange in cash
2026-06-30$25.92M*$11.34M*$6.39M*
2026-03-31-$33.52M-$25.08M$7.19M*-$51.45M
2025-12-31-$34.74M*$75.14M*$4.12M*
2025-09-30-$52.59M*$36.49M*$7.37M*
2025-06-30-$32.40M*-$31.81M*-$3.38M*
2025-03-31-$11.55M$7.93M$5.97M*$2.94M
2024-12-31-$8.00M*$35.70M*$4.14M*
2024-09-30-$28.88M*$3.70M*$3.10M*$227.00K*
2024-06-30-$29.97M*$52.10M*$2.37M*$461.00K*
2024-03-31-$41.71M$29.91M$2.12M$892.00K-$9.75M
2023-12-31-$19.61M*-$24.32M*$3.77M*
2023-09-30-$106.00K*-$12.79M*$6.56M*$256.00K*
2023-06-30$19.90M*-$34.39M*$0.00*$334.00K*
2023-03-31-$44.06M-$149.61M$0.00$490.00K*-$194.34M
2022-12-31$30.91M*-$17.06M*
2022-09-30-$126.79M*-$281.99M*
2022-06-30$273.01M*-$27.20M*$1.17M*
2022-03-31$100.22M-$26.37M-$3.13M*$70.51M
2021-12-31-$16.71M*-$1.15M*$0.00*$0.00*$1.83M*
2021-09-30-$5.93M*-$269.63M*$0.00*$0.00*$898.00K*
2021-06-30$157.68M*-$45.63M*-$107.00K*$1.71M*-$6.68M*
2021-03-31$109.55M-$15.84M-$1.72M$173.00K$91.68M
2020-12-31$1.28M*-$108.18M*-$2.97M*-$26.00K*$107.00K*$612.83M*
2020-09-30-$3.80M*-$3.88M*-$15.00M*$7.00K*$642.00K*
2020-06-30$25.98M*-$2.13M*$62.00K*-$662.00K*$127.00K*
2020-03-31-$764.00K-$5.58M-$2.03M$16.17M$124.00K$73.48M*$81.39M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Organon & Co. (OGN)United States$3.603B17.03
IDEAYA Biosciences, Inc. (IDYA)United States$3.540B-20.52
Indivior Pharmaceuticals, Inc. (INDV)$4.250B14.09
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51
Amylyx Pharmaceuticals, Inc. (AMLX)United States$3.361B-13.15
Enliven Therapeutics, Inc. (ELVN)United States$3.307B-35.07
Arcutis Biotherapeutics, Inc. (ARQT)United States$3.303B115.47